Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets

B2 Cell-based assays of CAG repeat instability in the huntingtin (HTT) gene

(2016) Tom Massey et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients

(2015) Nicola De Stefano et al.   Multiple Sclerosis Journal

Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients

(2015) Nicola De Stefano et al.   Multiple Sclerosis Journal

Clinical Relevance of Brain Volume Measures in Multiple Sclerosis

(2014) Nicola De Stefano et al.   CNS DRUGS

Brain atrophy in natalizumab-treated patients: A 3-year follow-up

(2014) J Sastre-Garriga et al.   Multiple Sclerosis Journal

Association between pathological and MRI findings in multiple sclerosis

(2012) Massimo Filippi et al.   LANCET NEUROLOGY

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

(2010) Gavin Giovannoni et al.   NEW ENGLAND JOURNAL OF MEDICINE